Toxicological Research

Korean Society of Toxicology & Korea Environmental Mutagen Society (한국독성학회)
권호 표지

Comparison of Single-Dose Toxicity by Intravenous Infusion or Bolus Injection with CKD-602, a Camptothecin Anticancer Agent in Rats (II): Hematological and Serum Biochemical, and Histopathological Changes

  • Published : 2004.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The toxicity of CKD-602 was investigated at doses of 3, 9, and 27 mg/kg in rats, when the same total dose of CKD-602 was administered over 24 hr-continuous infusion or bolus injection. At 3 and 9 mg/kg, the 24-hr infusion group showed a more decreased WBC count on day 3, compared with the bolus group. Administration of CKD-602 caused more toxic effects such as the significant decreases of RBC counts, hematocrit, hemoglobin, and platelet count on day 7 post-administarion in the 24-hr infusion group than in the bolus group. Administration of CKD-602 also caused histopathological changes such as extramedullary hemopoiesis of liver and spleen, hyperplasia of femoral bone marrow, and caecal dilation. These toxic effects were more severe in the 24-hr infusion group than in the bolus injection group, indicating that the toxicity of CKD-602 may be dependant upon the duration of administration.

Keywords

References

  1. Bleiberg, H. and Rothenberg, M.L. (1996): CPT-11: From DNA topology to clinical activity. Semi. Oncol., 23, 1-50
  2. Bozec, L., Bierling, P, Fromont, P, Levi, F., Debat, P, Cvitkovic, E. and Misset, J.L. (1998): Irinotecan-induced immune thrombocytopenia. Ann. Oncol., 9, 453-455
  3. Cass, I., Kuo, D.Y., Fields, AL., Runowicz, C.D. and Goldberg, G.L. (1998): Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan. Gynecol. Oncol., 69, 175-178
  4. Dahut, W, Harolod, N., Takimototo, C., Allegra, C., Chen, A, Hamilton, J.M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, Wand Grem, J. (1996): Phase I and pharmacokinetic study of 9aminocamptothecin given as a 72-hour infusion in adult cancer patients. J. Glin. Oncol., 14, 1236-1244
  5. Edelman, E.R. and Karnovsky, M.J. (1994): Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation, 89, 770-776 https://doi.org/10.1161/01.CIR.89.2.770
  6. Evans, J.G. and Kerry, P.J. (2000): Common pathological findings in continuous infusion studies. In: Guy healing and David Smith (eds.) Handbook of preclinical continuous intravenous infusion. Taylor & Francis, pp 253-264
  7. Flynn, J.L., Chan, J., Triebold, K.J., Dalton, O.K., Stewart, T.A. and Bloom, B.R. (1993): An essential role for interferon gamma in resistance to mycobacterium tuberculosis infection. Journal of Experimental Medicine, 178, 2249-2254 https://doi.org/10.1084/jem.178.6.2249
  8. Fujitani, T., Tada, Y and Yoneyama, M. (2004): Chlorpropham-induced splenotoxicity and its recovery in rats. Food Chem. Toxicol., 42, 1469-1477
  9. Gargosky, S.E., Tapanainen, P. and Rosenfeld, R.G. (1994): Administration of growth hormone (GH), but not insulinlike growth factor-I (IGF-I), by continuous infection can induced the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology, 134, 2267-2276 https://doi.org/10.1210/en.134.5.2267
  10. Greaves, P. (2000): Digestive system I, In: Histopathology of preclinical toxicity studies ($2^{nd}$ eds) Elsevier Science, pp. 398-401
  11. Gottlieb, J.A., Guarino, A.M., Call, J.B., Oliverio, V.T. and Block, J.B. (1970): Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother. Rep., 54, 461-470
  12. Hertzberg, R.P., Caranfa, M.J., Holden, K.G., Jakas, D.R., Gallagher, G., Mattern, M.R., Mong, S.M., Bartus, J.O., Johnson, R.K. and Kingsbury, WD. (1989): Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32, 715-720 https://doi.org/10.1021/jm00123a038
  13. Jung, L.L. and Zamboni, WC. (2001): Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it ? Drug. Resistance Updates, 4, 273-288
  14. Kasahara, K., Nishikawa, A., Furukawa, F., Ikezaki, S., Tanakamaru, Z., Lee, I.S., Imazawa, T. and Hirose, (2002): A chronic toxicity study of josamycin in F344 rats. Food Chem. Toxicol., 40, 1017-1022.
  15. Kim, C.Y., Imai, Y, Ito, K., Hashimoto, J., Nobunaga, T., Satoh, H. and Abe, K. (1996): Analysis of circadian variation of blood pressure and heart rate in dexamethasoneinduced hypertensive rats. Clin. Exper. Hypertension, 18, 65-76
  16. Kolimannsberger, C., Mross, K., Jakob, A, Kanz, L. and Bokemyer, C. (1999): Topotecan - A novel topoisomerase I inhibitor: Pharmacology and clinical experience. Oncology, 56, 1-12 https://doi.org/10.1159/000011923
  17. Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y., Jew, S.S., Park, J.G. and Hong, C.I. (1998): Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)- camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res., 21, 581-590.
  18. Moertel, C.G., Schutt, AJ., Reitmeier, R.J. and Hahn, R.G. (1972): Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101
  19. Pizzolato, J.F. and Saltz, L.B. (2003): The camptothecins. Lancet, 361, 2235-2242
  20. Rothenberg, M.L. (1997): Topoisomerase I inhibitors: review and update. Ann. Oncol., 8, 837-855
  21. Slichenmyer, WJ. and Rowinsky, E.K. (1993): The current status of amptothecin analogues as antitumor agents. J. Natl. Cancer Inst., 85, 271-291 https://doi.org/10.1093/jnci/85.4.271
  22. Takimoto, C.H., Wright, J. and Arbuck, S.G. (1998): Clinical applications of the camptothecins. Biochirn. Biophys. Acta, 1400,107-119
  23. Thompson, J., Stewart, C.F. and Houghton, P.J. (1998): Animal models for studyinq the action of topoisomerase I targeted drugs. Biochim. Biophys Acta, 1400, 301-319
  24. Toti, P., De Felice, C., Stumpo, M., Schrfeld, K., Di Leo, L., Vatti, R., Bianciardi, G., Buonocore, G., Seemayer, TA and Luzi, P. (2000): Acute thymic involution in fetuses and neonates with chorioamnionitis. Hum. Pathol., 31, 1121-1128
  25. Tomas, F.M., Lemmey, A.B., Read, L.C. and Ballard, F.J. (1996): Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J. of Endocrinology, 150, 77-84 https://doi.org/10.1677/joe.0.1500077
  26. Wall, ME, Wani, M.C. and Cook, C.E. (1966): Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-3890 https://doi.org/10.1021/ja00968a057